Genomic impact of transient low-dose decitabine treatment on primary AML cells-Reference-Cited by-同舟云学术

Genomic impact of transient low-dose decitabine treatment on primary AML cells

Published:2013-02-28 Issue:9 Volume:121 Page:1633-1643
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Klco Jeffery M.¹,Spencer David H.¹,Lamprecht Tamara L.²,Sarkaria Shawn M.²,Wylie Todd³,Magrini Vincent³,Hundal Jasreet³,Walker Jason³,Varghese Nobish¹,Erdmann-Gilmore Petra⁴,Lichti Cheryl F.⁴⁵,Meyer Matthew R.⁴,Townsend R. Reid⁴,Wilson Richard K.³,Mardis Elaine R.³,Ley Timothy J.²³

Affiliation:

1. Departments of Pathology and Immunology and

2. Internal Medicine, Division of Oncology, Section of Stem Cell Biology,

3. The Genome Institute, and

4. Department of Internal Medicine, Washington University School of Medicine, St Louis, MO; and

5. Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

Abstract

Key Points Decitabine treatment of in vitro expanded primary AML samples leads to global hypomethylation. Highly methylated CpGs are most affected by decitabine-induced hypomethylation, with little influence on transcriptional activity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/9/1633/1369476/zh800913001633.pdf

Reference50 articles.

1. Anthracycline dose intensification in acute myeloid leukemia.;Fernandez;N Engl J Med,2009

2. Strategies in the treatment of acute myeloid leukemia.;Lowenberg;Haematologica,2004

3. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.;Grimwade;Blood,2010

4. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.;Schlenk;N Engl J Med,2008

5. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.;Cashen;J Clin Oncol,2010

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition;2024-09-08

2. Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cellsin vivo;2024-07-23

3. Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax;Clinical Epigenetics;2024-03-26

4. Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia;Experimental Hematology & Oncology;2024-02-20

5. Modeling Acute Myeloid Leukemia Using StarPEG-Heparin Hydrogels;Methods in Molecular Biology;2024